Biotech Values

[DewDiligence]

GILD—Nor do we know what [duration of treatment] the FDA will approve.

True; however, on the MS webcast yesterday, COO John Milligan sounded very confident that the FDA will approve both 8- and 12-week regimens. It’s close enough to GILD’s PDUFA date (10/10/14) that Milligan would presumably know if the FDA were thinking of not approving the 8-week regimen.